CHEK2 and breast carcinoma: There is less evidence regarding the benefit ofMRI screening in patients with those less common mutations than there isregarding its benefit in patients with mutations in the BRCA1 or BRCA2 gene.However, Lowry et al.(18)suggested that annual MRI screening starting at 30–35 years of age, followed byannual MRI and mammography starting at age 40, reduces breast cancer mortalityby more than 50% for women with the ATM, CHEK2, or PALB2 pathogenic variant.